Table of contents

  • Non-Small-Cell Lung Cancer - Current Treatment - Detailed Expanded Analysis: Treatment Sequencing (EU5)
    • Treatment Sequencing | Non-Small-Cell Lung Cancer | EU5 September 2020

Author(s): Vandana, M.Pharm

Vandana is a Research Associate in the oncology team at Decision Resources Group. Her current work is focused on performing market research in several oncology indications across the major pharmaceutical markets.

Prior to joining DRG, she worked as a Business Analyst (Digital marketing) at Iquanti, Bangalore. She has also previously worked as Analyst in WNS, Noida, India. She has worked on multiple client projects involving competitive intelligence, forecasting, pipeline analysis, keywords research and product/company profiling. She has earned her Master's in Pharmacology from DIPSAR, New Delhi, India.


Related Reports

Non-Small-Cell Lung Cancer - Landscape & Forecast - Disease Landscape & Forecast

Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers.

View Details

Non-Small-Cell Lung Cancer | Disease Landscape and Forecast | G7 | 2020

Non-small-cell lung cancer (NSCLC), a dynamic oncology indication with high unmet need, remains a key area of focus for drug developers. NSCLC is defined by driver mutations, and treatment is becom...

View Details

Non-Small-Cell Lung Cancer - Geographic Focus: China - Non-Small-Cell Lung Cancer - China In-Depth (China)

Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, with multiple targeted and biomarker-driven therap...

View Details

Non-Small-Cell Lung Cancer - Epidemiology - Emerging Markets

DRG Epidemiology’s coverage of non-small-cell lung cancer (NSCLC) comprises epidemiological estim...

View Details